Document is current

Article History

Received: 4 June 2024

Accepted: 19 June 2024

First Online: 3 July 2024

Declarations

:

: This position paper contains no original data or personal information and thus issues of ethics, informed consent, and patient confidentiality do not apply.

: JA Kanis led the team that developed FRAX as director of the WHO Collaborating Centre for Metabolic Bone Diseases at Sheffield; he is a director of Osteoporosis Research Ltd that maintains FRAX. EV McCloskey, M Lorentzon, NC Harvey, M Schini, E Liu, L Vandenput and H Johansson are members of the FRAX team. JA Kanis, NC Harvey and EV McCloskey are members of the advisory body to the National Osteoporosis Guideline Group.B Abrahamsen has received consultancy/lecture fees/institutional grant funding from UCB, Amgen, Pharmacosmos, Kyowa-Kirin and Gedeon-Richter outside the current work.Olivier Bruyère has received consulting or lecture fees from Amgen, Aptissen, Biophytis, IBSA, Mylan, Novartis, Nutricia, Orifarm, Sanofi, UCB and Viatris outside the current work.JJ Carey is funded by the Health Research Board of Ireland and has received consultancy/lecture fees/grant funding and honoraria from Abbvie, Amgen, Eli-Lily, Pfizer, Consilient Health and UCB, all outside the presented work.M Diaz-Curiel has received consultancy/lecture fees, from Amgen, Takeda, Mereo and Kaiowa-Kirin.HP Dimai has received consultancy/lecture fees/grant funding/honoraria from Amgen, Braincon, Daiichi-Sankyo, Eli Lilly, Gedeon Richter, Medtronic, Merck Sharp & Dohme, Novartis, Nycomed, Servier, Sinapharm, UCB.NC Harvey has received consultancy/lecture fees/honoraria/grant funding from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Radius Health, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Theramex and Internis Pharma.Willem Lems has received speaker fees/consultancy fees from Amgen, UCB, Pfizer and Galapagos (all outside this manuscript).EM Lewiecki has received consultancy/lecture fees/honoraria/grant funding from Amgen, Radius Health, Kyowa Kirin, Ultragenyx, Ascendis and Angitia.M Lorentzon has received lecture fees from Amgen, Lilly, Meda, Renapharma and UCB Pharma and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma, Parexel International and Consilient Health, all outside the presented work.EV McCloskey has received consultancy/lecture fees/grant funding/honoraria from AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, Gilead, GSK, Hologic, Internis, Lilly, Merck, Novartis, ObsEva, Pfizer, Radius Health, Redx Oncology, Roche, Sanofi Aventis, UCB, ViiV, Warner Chilcott and I3 Innovus.Alexandra Papaioannou has received funding from Amgen Research and honorarium.M Schini received funding for her fellowship from the Medical Research Council Centre of Excellence for Musculoskeletal Ageing, from the Osteoporosis 2000 support group and from Roche Diagnostics and honoraria from MA Health care and Kyowa Kirin—all unrelated to this work.S Silverman has received consultancy/grant support from Amgen and Radius.JD Adachi, M Alokai, F Borgstrom, P Clark, C Cooper, MD Curiel, EM Curtis, EM Dennison, D Grigorie, H Johansson, E Liu, M Hiligsmann, P Khashayar, R Lorenc, J-Y Reginster, R Rizzoli, EJ Shiroma, EM Simonsick, M Sosa-Henríquez P Szulc, L Vandenput and K Ward declare no competing interests in relation to this work.